Targinta AB
Company

Targinta AB

Biotechnology Research Lund, Skåne Län, Se 1 employees
Employees
1
Contacts
1
Emails
1

Targinta AB Overview

Headquarters
Lund, Skåne Län, Se
Website
www.targinta.se
Industry
Biotechnology Research
Employees
1
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)

About Targinta AB

Targinta is a preclinical stage oncology biotech company, developing first-in-class therapeutic antibodies and ADCs for treatment of aggressive cancers, such as glioblastoma and triple-negative breast cancer, based on a unique and patent-protected target. The pipeline includes TARG10, which is a function-blocking antibody in preclinical development targeting integrin α10. In addition, Targinta’s pipeline includes TARG9, an antibody-drug conjugate (ADC) targeting integrin α10. Targinta is a wholly owned subsidiary of Xintela AB (publ) and is headquartered in Lund, Sweden.

Targinta AB Contact Details

People in AeroLeads
1
With contact data
1
Email contacts
1
100.0% coverage

Targinta AB Org Chart

Sample employees and titles
Name Title Contact
Greg Batcheller
Email

Compare Similar Companies to Targinta AB